MSD and Daiichi Sankyo have announced first subject dosing in the IDeate-Prostate01 Phase III trial of ifinatamab deruxtecan ...

Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial ...

Merck just kicked off its Phase 3 IDeate-Prostate01 trial, handing the first dose of ifinatamab deruxtecan to a patient ...

The first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating the efficacy and safety of investigational ifinatamab deruxtecan (I-DXd) versus docetaxel in patients with metastatic ...

Three United Nations agencies warned on Thursday of looming famine in an area of South Sudan facing violent conflict. People in 11 of 13 counties in South Sudan’s Upper Nile ...

MacroGenics' recent royalty deal extends cash runway, but liquidity concerns remain, and further asset sales or dilution may ...

The Palestinian Health Ministry says Palestinians desperately trying to access aid in Gaza have come under fire again, killing 36 people and wounding 207. Experts and humanitarian aid workers say ...

映恩生物-B（09606）早盘一度涨超13%，盘中高见243.2港元，创上市新高。截至发稿，股价上涨11.66%，报239.40港元，成交额8327.82万港元。

再鼎医药算是本次ASCO大会上最靓的仔之一，DLL3 ADC同时兼具全球first in class兼具best in ...

SHANGHAI, China and CHICAGO, IL, USA I June 5, 2025 I The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio ...

Supports plans to advance the RV01 program to first-in-human therapeutic basket study in solid tumour cancers Data completes ...